FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1498-1505 May 21, 1998 Number 21 Next

	Full Text PDF Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Activation of platelets is central to the pathophysiology of unstable angina. We studied whether inhibition of the final common pathway for platelet aggregation with tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist, would improve clinical outcome in this condition.

Methods In a double-blind study, we randomly assigned 3232 patients who were already receiving aspirin to additional treatment with intravenous tirofiban or heparin for 48 hours. The primary end point was a composite of death, myocardial infarction, or refractory ischemia at 48 hours.

Results The incidence of the composite end point was 32 percent lower at 48 hours in the group that received tirofiban (3.8 percent, vs. 5.6 percent with heparin; risk ratio, 0.67; 95 percent confidence interval, 0.48 to 0.92; P=0.01). Percutaneous revascularization was performed in 1.9 percent of the patients during the first 48 hours. At 30 days, the frequency of the composite end point (with the addition of readmission for unstable angina) was similar in the two groups (15.9 percent in the tirofiban group vs. 17.1 percent in the heparin group, P=0.34). There was a trend toward a reduction in the rate of death or myocardial infarction with tirofiban (a rate of 5.8 percent, as compared with 7.1 percent in the heparin group; risk ratio, 0.80; 95 percent confidence interval, 0.61 to 1.05; P=0.11), and mortality was 2.3 percent, as compared with 3.6 percent in the heparin group (P=0.02). Major bleeding occurred in 0.4 percent of the patients in both groups. Reversible thrombocytopenia occurred more frequently with tirofiban than with heparin (1.1 percent vs. 0.4 percent, P=0.04).

Conclusions Tirofiban was generally well tolerated and, as compared with heparin, reduced ischemic events during the 48-hour infusion period, during which revascularization procedures were not performed. The incidence of refractory ischemia and myocardial infarction was not reduced at 30 days, but mortality was lower among the patients given tirofiban. Platelet inhibition with aspirin plus tirofiban may have a role in the management of unstable angina.

Source Information

Address reprint requests to Professor Harvey White at the Cardiology Department, Green Lane Hospital, Private Bag 92 189, Auckland 1030, New Zealand.

Full Text of this Article

Related Letters:

Tirofiban in Unstable Coronary Disease
Liron M., Théroux P., White H. D., The PRISM Study Investigators , Chesebro J. H., Badimon J. J.
Extract | Full Text  
N Engl J Med 1998; 339:1163-1165, Oct 15, 1998. Correspondence

Management of Non–Q-Wave Myocardial Infarction
Bedell S. E., Graboys T. B., Ravid S., Thompson R. C., Roe M. T., Bowen T. E., Topol E. J., Huitink J. M., Bax J. J., Boden W. E., O'Rourke R. A., Crawford M. H.
Extract | Full Text  
N Engl J Med 1998; 339:1395-1398, Nov 5, 1998. Correspondence

This article has been cited by other articles:

• Nikolsky, E., Stone, G. W., Kirtane, A. J., Dangas, G. D., Lansky, A. J., McLaurin, B., Lincoff, A. M., Feit, F., Moses, J. W., Fahy, M., Manoukian, S. V., White, H. D., Ohman, E. M., Bertrand, M. E., Cox, D. A., Mehran, R. (2009). Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.. J Am Coll Cardiol 54: 1293-1302 [Abstract] [Full Text]  
• Valgimigli, M., Biondi-Zoccai, G., Tebaldi, M., van 't Hof, A. W.J., Campo, G., Hamm, C., ten Berg, J., Bolognese, L., Saia, F., Danzi, G. B., Briguori, C., Okmen, E., King, S. B., Moliterno, D. J., Topol, E. J. (2009). Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J 0: ehp376v1-ehp376 [Abstract] [Full Text]  
• Giugliano, R. P., White, J. A., Bode, C., Armstrong, P. W., Montalescot, G., Lewis, B. S., van `t Hof, A., Berdan, L. G., Lee, K. L., Strony, J. T., Hildemann, S., Veltri, E., Van de Werf, F., Braunwald, E., Harrington, R. A., Califf, R. M., Newby, L. K., the EARLY ACS Investigators, (2009). Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes. NEJM 360: 2176-2190 [Abstract] [Full Text]  
• Honda, S., Shirotani-Ikejima, H., Tadokoro, S., Maeda, Y., Kinoshita, T., Tomiyama, Y., Miyata, T. (2009). Integrin-linked kinase associated with integrin activation. Blood 113: 5304-5313 [Abstract] [Full Text]  
• Potsis, T. Z., Katsouras, C., Goudevenos, J. A. (2009). Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. ANGIOLOGY 60: 148-158 [Abstract]  
• Smyth, S. S., Woulfe, D. S., Weitz, J. I., Gachet, C., Conley, P. B., Goodman, S. G., Roe, M. T., Kuliopulos, A., Moliterno, D. J., French, P. A., Steinhubl, S. R., Becker, R. C., for the 2008 Platelet Colloquium Participants, (2009). G-Protein-Coupled Receptors as Signaling Targets for Antiplatelet Therapy. Arterioscler. Thromb. Vasc. Bio. 29: 449-457 [Abstract] [Full Text]  
• Hollenberg, S. M. (2009). Acute Coronary Syndromes. ACCP Crit Care Med Brd Rev 20: 129-144 [Full Text]  
• Hamm, C. W., Möllmann, H., Bassand, J.-P., van de Werf, F. (2009). CHAPTER 16 Acute Coronary Syndromes. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Marzocchi, A., Manari, A., Piovaccari, G., Marrozzini, C., Marra, S., Magnavacchi, P., Sangiorgio, P., Marinucci, L., Taglieri, N., Gordini, G., Binetti, N., Guiducci, V., Franco, N., Reggiani, M. L.-B., Saia, F., on behalf of the FATA Investigators, (2008). Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J 29: 2972-2980 [Abstract] [Full Text]  
• Herrler, T., Bohm, M., Heeschen, C. (2008). More good reasons for adherence to statin therapy during acute coronary syndromes. Eur Heart J 29: 2061-2063 [Full Text]  
• Coons, J. C, Battistone, S. (2008). 2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies. The Annals of Pharmacotherapy 42: 989-1001 [Abstract] [Full Text]  
• Patrono, C., Baigent, C., Hirsh, J., Roth, G. (2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S [Abstract] [Full Text]  
• Harrington, R. A., Becker, R. C., Cannon, C. P., Gutterman, D., Lincoff, A. M., Popma, J. J., Steg, G., Guyatt, G. H., Goodman, S. G. (2008). Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 670S-707S [Abstract] [Full Text]  
• Dabbous, O H, Anderson, F A Jr, Gore, J M, Eagle, K A, Fox, K A A, Mehta, R H, Goldberg, R J, Agnelli, G, Steg, P G, for the GRACE Investigators, (2008). Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes. Heart 94: 159-165 [Abstract] [Full Text]  
• Albert, M. A., Halevy, N., Antman, E. M. (2008). Preoperative Evaluation for Cardiac Surgery. Card Surg Adult 3: 261-280 [Full Text]  
• Gitt, A. K., Betriu, A. (2008). Antiplatelet therapy in acute coronary syndromes. Eur Heart J Suppl 10: A4-A12 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: 652-726 [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Alexander, K. P., Newby, L. K., Cannon, C. P., Armstrong, P. W., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., Gore, J. M., Krumholz, H. M., Ohman, E. M. (2007). Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology. Circulation 115: 2549-2569 [Abstract] [Full Text]  
• Hernandez, A. V, Westerhout, C. M, Steyerberg, E. W, Ioannidis, J. P A, Bueno, H., White, H., Theroux, P., Moliterno, D. J, Armstrong, P. W, Califf, R. M, Wallentin, L. C, Simoons, M. L, Boersma, E. (2007). Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart 93: 450-455 [Abstract] [Full Text]  
• Raveendran, G., Ting, H. H., Best, P. J., Holmes, D. R. Jr, Lennon, R. J., Singh, M., Bell, M. R., Long, K. H., Rihal, C. S. (2007). Eptifibatide vs Abciximab as Adjunctive Therapy During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. Mayo Clin Proc. 82: 196-202 [Abstract] [Full Text]  
• Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., Stevenson, W. (2006). The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions. Circulation 114: 2871-2891 [Full Text]  
• Westerhout, C. M., Hernandez, A. V., Steyerberg, E. W., Bueno, H., White, H., Theroux, P., Moliterno, D. J., Armstrong, P. W., Califf, R. M., Wallentin, L. C., Simoons, M. L., Boersma, E. (2006). Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 27: 2956-2961 [Abstract] [Full Text]  
• Montalescot, G. (2006). Glycoprotein IIb/IIIa Inhibitors in the Elderly: Fear of Age or Age of Fear?. Circulation 114: 2004-2006 [Full Text]  
• Bertrand, M. E., Van Belle, E. (2006). Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes. Eur Heart J Suppl 8: G59-G63 [Abstract] [Full Text]  
• Alexander, K. P., Chen, A. Y., Newby, L. K., Schwartz, J. B., Redberg, R. F., Hochman, J. S., Roe, M. T., Gibler, W. B., Ohman, E. M., Peterson, E. D., for the CRUSADE (Can Rapid risk stratification of, (2006). Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative. Circulation 114: 1380-1387 [Abstract] [Full Text]  
• Rao, S. V., O'Grady, K., Pieper, K. S., Granger, C. B., Newby, L. K., Mahaffey, K. W., Moliterno, D. J., Lincoff, A. M., Armstrong, P. W., Van de Werf, F., Califf, R. M., Harrington, R. A. (2006). A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes. J Am Coll Cardiol 47: 809-816 [Abstract] [Full Text]  
• Glaser, R., Glick, H. A., Herrmann, H. C., Kimmel, S. E. (2006). The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis. J Am Coll Cardiol 47: 529-537 [Abstract] [Full Text]  
• Vorchheimer, D. A., Becker, R. (2006). Platelets in Atherothrombosis. Mayo Clin Proc. 81: 59-68 [Abstract] [Full Text]  
• Shanmugam, G. (2005). Tirofiban and emergency coronary surgery. Eur. J. Cardiothorac. Surg. 28: 546-550 [Abstract] [Full Text]  
• Elsasser, A., Hamm, C. W. (2005). Percutaneous coronary intervention guidelines: new aspects for the interventional treatment of acute coronary syndromes. Eur Heart J Suppl 7: K5-K9 [Abstract] [Full Text]  
• Cavallini, C., Chirillo, F. (2005). Non-ST-elevation acute coronary syndromes management: a fresh look at glycoprotein IIb/IIIa inhibitors. Eur Heart J Suppl 7: K10-K14 [Abstract] [Full Text]  
• Coons, J. C, Seybert, A. L, Saul, M. I, Kirisci, L., Kane-Gill, S. L (2005). Outcomes and Costs of Abciximab Versus Eptifibatide for Percutaneous Coronary Intervention. The Annals of Pharmacotherapy 39: 1621-1626 [Abstract] [Full Text]  
• Tong, K. L., Kaul, S., Wang, X.-Q., Rinkevich, D., Kalvaitis, S., Belcik, T., Lepper, W., Foster, W. A., Wei, K. (2005). Myocardial Contrast Echocardiography Versus Thrombolysis in Myocardial Infarction Score in Patients Presenting to the Emergency Department With Chest Pain and a Nondiagnostic Electrocardiogram. J Am Coll Cardiol 46: 920-927 [Abstract] [Full Text]  
• Authors/Task Force Members, , Silber, S., Albertsson, P., Aviles, F. F., Camici, P. G., Colombo, A., Hamm, C., Jorgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., Urban, P., Stone, G. W., Wijns, W. (2005). Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26: 804-847 [Full Text]  
• Matthai, W. H. Jr (2005). Thrombocytopenia in Cardiovascular Patients: Diagnosis and Management. Chest 127: 46S-52S [Abstract] [Full Text]  
• Heeschen, C., Hamm, C. W., Mitrovic, V., Lantelme, N.-H., White, H. D., for the Platelet Receptor Inhibition in Ischemic S, (2004). N-Terminal Pro-B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes. Circulation 110: 3206-3212 [Abstract] [Full Text]  
• Wiggins, B. S., Spinler, S. (2004). Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes. Journal of Pharmacy Practice 17: 347-369 [Abstract]  
• Fox, K. A.A., Mehta, S. R., Peters, R., Zhao, F., Lakkis, N., Gersh, B. J., Yusuf, S. (2004). Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110: 1202-1208 [Abstract] [Full Text]  
• Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full Text]  
• Harrington, R. A., Becker, R. C., Ezekowitz, M., Meade, T. W., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H. (2004). Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 513S-548S [Abstract] [Full Text]  
• Goto, S., Tamura, N., Ishida, H. (2004). Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 44: 316-323 [Abstract] [Full Text]  
• Blazing, M. A., de Lemos, J. A., White, H. D., Fox, K. A. A., Verheugt, F. W. A., Ardissino, D., DiBattiste, P. M., Palmisano, J., Bilheimer, D. W., Snapinn, S. M., Ramsey, K. E., Gardner, L. H., Hasselblad, V., Pfeffer, M. A., Lewis, E. F., Braunwald, E., Califf, R. M., for the A to Z Investigators, (2004). Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and Aspirin: A Randomized Controlled Trial. JAMA 292: 55-64 [Abstract] [Full Text]  
• Day, J R S, Malik, I S, Weerasinghe, A, Poullis, M, Nadra, I, Haskard, D O, Taylor, K M, Landis, R C (2004). Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention. Heart 90: 794-799 [Abstract] [Full Text]  
• Behan, M W H, Storey, R F (2004). Antiplatelet therapy in cardiovascular disease. Postgrad. Med. J. 80: 155-164 [Abstract] [Full Text]  
• Okamatsu, K., Takano, M., Sakai, S., Ishibashi, F., Uemura, R., Takano, T., Mizuno, K. (2004). Elevated Troponin T Levels and Lesion Characteristics in Non-ST-Elevation Acute Coronary Syndromes. Circulation 109: 465-470 [Abstract] [Full Text]  
• Baker, C. S R (2004). Learning on the Web. Case 3: acute chest pain.. Heart 90: 112-112 [Full Text]  
• Cohen, M., Gensini, G. F., Maritz, F., Gurfinkel, E. P., Huber, K., Timerman, A., Krzeminska-Pakula, M., Danchin, N., White, H. D., Santopinto, J., Bigonzi, F., Hecquet, C., Vittori, L., TETAMI Investigators, (2003). The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized trial. J Am Coll Cardiol 42: 1348-1356 [Abstract] [Full Text]  
• Prasad, A., Mathew, V., Holmes, D. R Jr., Gersh, B. J (2003). Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials. Eur Heart J 24: 1544-1553 [Abstract] [Full Text]  
• Peterson, E. D., Pollack, C. V. Jr, Roe, M. T., Parsons, L. S., Littrell, K. A., Canto, J. G., Barron, H. V., National Registry of Myocardial Infarction (NRMI), (2003). Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: Observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 42: 45-53 [Abstract] [Full Text]  
• Crouch, M. A, Nappi, J. M, Cheang, K. I (2003). Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome. The Annals of Pharmacotherapy 37: 860-875 [Abstract] [Full Text]  
• Hyde, T A, French, J K, Wong, C-K, Edwards, C, Whitlock, R M L, White, H D (2003). Associations between ST depression, four year mortality, and in-hospital revascularisation in unselected patients with non-ST elevation acute coronary syndromes. Heart 89: 490-495 [Abstract] [Full Text]  
• Brown, D L (2003). Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart 89: 535-537 [Abstract] [Full Text]  
• Rezkalla, S. H., Benz, M. (2003). Antiplatelet Therapy from Clinical Trials to Clinical Practice. Clin Med Res 1: 101-104 [Abstract] [Full Text]  
• Lee, D. P., Herity, N. A., Hiatt, B. L., Fearon, W. F., Rezaee, M., Carter, A. J., Huston, M., Schreiber, D., DiBattiste, P. M., Yeung, A. C. (2003). Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial. Circulation 107: 1497-1501 [Abstract] [Full Text]  
• Freeman, R. V., Mehta, R. H., Al Badr, W., Cooper, J. V., Kline-Rogers, E., Eagle, K. A. (2003). Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41: 718-724 [Abstract] [Full Text]  
• Thambyrajah, J, De Belder, M.A (2003). Management of non ST-segment elevation acute coronary syndromes--continuing the search for the bad guys. Eur Heart J 24: 490-493 [Full Text]  
• Gowda, M. S., Vacek, J. L., Lakkireddy, D.J., Brosnahan, K., Beauchamp, G. D. (2003). Differential Benefits and Outcomes of Tirofiban vs Abciximab for Acute Coronary Syndromes in Current Clinical Practice. ANGIOLOGY 54: 211-218 [Abstract]  
• Janzon, M, Levin, L-A, Swahn, E (2003). Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial. Heart 89: 287-292 [Abstract] [Full Text]  
• Cannon, C. P. (2003). Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: Insights from the TACTICS TIMI-18 trial. J Am Coll Cardiol 41: 43S-48S [Abstract] [Full Text]  
• Moliterno, D. J., Chan, A. W. (2003). Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. J Am Coll Cardiol 41: 49S-54S [Abstract] [Full Text]  
• Nissen, S. E. (2003). Pathobiology, not angiography, should guide managementin acute coronary syndrome/non-ST-segment elevation myocardial infarction: The non-interventionist's perspective. J Am Coll Cardiol 41: 103S-112S [Abstract] [Full Text]  
• Boden, W. E. (2003). "Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era. J Am Coll Cardiol 41: 113S-122S [Abstract] [Full Text]  
• Petronio, A.S, Rovai, D, Musumeci, G, Baglini, R, Nardi, C, Limbruno, U, Palagi, C, Volterrani, D, Mariani, M (2003). Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J 24: 67-76 [Abstract] [Full Text]  
• Bhatt, D. L., Lee, B. I., Casterella, P. J., Pulsipher, M., Rogers, M., Cohen, M., Corrigan, V. E., Ryan, T. J. Jr, Breall, J. A., Moses, J. W., Eaton, G. M., Sklar, M. A., Lincoff, A. M. (2003). Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study. J Am Coll Cardiol 41: 20-25 [Abstract] [Full Text]  
• Albert, M. A., Antman, E. M. (2003). Preoperative Evaluation for Cardiac Surgery. Card Surg Adult 2: 235-248 [Full Text]  
• Glaser, R., Herrmann, H. C., Murphy, S. A., Demopoulos, L. A., DiBattiste, P. M., Cannon, C. P., Braunwald, E. (2002). Benefit of an Early Invasive Management Strategy in Women With Acute Coronary Syndromes. JAMA 288: 3124-3129 [Abstract] [Full Text]  
• Yarlagadda, R. K., Boden, W. E. (2002). Cardioprotective effects of an early invasive strategy for non-ST-segment elevationacute coronary syndromes: Are we all becoming "interventional" cardiologists?. J Am Coll Cardiol 40: 1915-1918 [Full Text]  
• Bertrand, M. E., Simoons, M. L., Fox, K. A.A., Wallentin, L. C., Hamm, C. W., McFadden, E., De Feyter, P. J., Specchia, G., Ruzyllo, W. (2002). Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 23: 1809-1840 [Full Text]  
• Sheridan, P J, Crossman, D C (2002). Critical review of unstable angina and non-ST elevation myocardial infarction. Postgrad. Med. J. 78: 717-726 [Abstract] [Full Text]  
• Chun, R., Orser, B. A., Madan, M. (2002). Platelet Glycoprotein IIb/IIIa Inhibitors: Overview and Implications for the Anesthesiologist. Anesth. Analg. 95: 879-888 [Full Text]  
• Antman, E.M. (2002). 'I can see clearly now': a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J 23: 1408-1411 [Full Text]  
• Roffi, M., Chew, D.P., Mukherjee, D., Bhatt, D.L., White, J.A., Moliterno, D.J., Heeschen, C., Hamm, C.W., Robbins, M.A., Kleiman, N.S., Theroux, P., White, H.D., Topol, E.J. (2002). Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J 23: 1441-1448 [Abstract] [Full Text]  
• Bougie, D. W., Wilker, P. R., Wuitschick, E. D., Curtis, B. R., Malik, M., Levine, S., Lind, R. N., Pereira, J., Aster, R. H. (2002). Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100: 2071-2076 [Abstract] [Full Text]  
• Califf, R. M., DeMets, D. L. (2002). Principles From Clinical Trials Relevant to Clinical Practice: Part I. Circulation 106: 1015-1021 [Full Text]  
• DeMets, D. L., Califf, R. M. (2002). Lessons Learned From Recent Cardiovascular Clinical Trials: Part I. Circulation 106: 746-751 [Full Text]  
• Meier, M. A., Al-Badr, W. H., Cooper, J. V., Kline-Rogers, E. M., Smith, D. E., Eagle, K. A., Mehta, R. H. (2002). The New Definition of Myocardial Infarction: Diagnostic and Prognostic Implications in Patients With Acute Coronary Syndromes. Arch Intern Med 162: 1585-1589 [Abstract] [Full Text]  
• Khot, U. N., Nissen, S. E. (2002). Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. J Am Coll Cardiol 40: 218-219 [Abstract] [Full Text]  
• Quinn, M. J., Plow, E. F., Topol, E. J. (2002). Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?. Circulation 106: 379-385 [Full Text]  
• Harding, S A, Boon, N A, Flapan, A D (2002). Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?. Heart 88: 11-14 [Abstract] [Full Text]  
• Cohen, V., Murphy, D. G., Williams, J. (2002). Review of the Current ACS Practice Guideline to Develop an Ischemic Chest Pain Protocol. Journal of Pharmacy Practice 15: 250-266 [Abstract]  
• Leebeek, F.W.G., Boersma, E., Cannon, C.P., van de Werf, F.J.J., Simoons, M.L. (2002). Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. Eur Heart J 23: 444-457 [Full Text]  
• Gensini, G.F., Dilaghi, B. (2002). The unstable plaque. Eur Heart J Suppl 4: B22-B27 [Abstract]  
• Prieto, A. R, Ma, H., Huang, R., Khan, G., Schwartz, K. A, Hage-Korban, E. E, Schmaier, A. H, Davis, J. M, Hasan, A. A.K, Abela, G. S (2002). Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. Cardiovasc Res 53: 984-992 [Abstract] [Full Text]  
• White, H. D., Wong, C. K. (2002). Risk stratification and treatment benefits in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 23: 187-191 [Full Text]  
• (2002). Randomized, Placebo-Controlled Trial of Titrated Intravenous Lamifiban for Acute Coronary Syndromes. Circulation 105: 316-321 [Abstract] [Full Text]  
• Labinaz, M., Kilaru, R., Pieper, K., Marso, S. P., Kitt, M. M., Simoons, M. L., Califf, R. M., Topol, E. J., Armstrong, P. W., Harrington, R. A. (2002). Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting: Results From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. Circulation 105: 322-327 [Abstract] [Full Text]  
• Baumbach, A., Karsch, K. R. (2002). Pricing a year of life: a necessary exercise in modern health care. Eur Heart J 23: 5-7 [Full Text]